Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect

Abstract The use of live, genetically modified bacteria as delivery vehicles for biologics is of considerable interest scientifically and has attracted significant commercial investment. We have pioneered the use of the commensal gut bacterium Bacteroides ovatus for the oral delivery of therapeutics...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Udo Wegmann, Ana Lucia Carvalho, Martin Stocks, Simon R. Carding
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d47528c7b1b741b89f5e48981a26bc68
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d47528c7b1b741b89f5e48981a26bc68
record_format	dspace
spelling	oai:doaj.org-article:d47528c7b1b741b89f5e48981a26bc682021-12-02T12:32:19ZUse of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect10.1038/s41598-017-02591-62045-2322https://doaj.org/article/d47528c7b1b741b89f5e48981a26bc682017-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-02591-6https://doaj.org/toc/2045-2322Abstract The use of live, genetically modified bacteria as delivery vehicles for biologics is of considerable interest scientifically and has attracted significant commercial investment. We have pioneered the use of the commensal gut bacterium Bacteroides ovatus for the oral delivery of therapeutics to the gastrointestinal tract. Here we report on our investigations of the biological safety of engineered B. ovatus bacteria that includes the use of thymineless death as a containment strategy and the potential for the spread of transgenes in vivo in the mammalian gastrointestinal tract. We demonstrate the ability of GM-strains of Bacteroides to survive thymine starvation and overcome it through the exchange of genetic material. We also provide evidence for horizontal gene transfer in the mammalian gastrointestinal tract resulting in transgene-carrying wild type bacteria. These findings sound a strong note of caution on the employment of live genetically modified bacteria for the delivery of biologics.Udo WegmannAna Lucia CarvalhoMartin StocksSimon R. CardingNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-7 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Udo Wegmann Ana Lucia Carvalho Martin Stocks Simon R. Carding Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect
description	Abstract The use of live, genetically modified bacteria as delivery vehicles for biologics is of considerable interest scientifically and has attracted significant commercial investment. We have pioneered the use of the commensal gut bacterium Bacteroides ovatus for the oral delivery of therapeutics to the gastrointestinal tract. Here we report on our investigations of the biological safety of engineered B. ovatus bacteria that includes the use of thymineless death as a containment strategy and the potential for the spread of transgenes in vivo in the mammalian gastrointestinal tract. We demonstrate the ability of GM-strains of Bacteroides to survive thymine starvation and overcome it through the exchange of genetic material. We also provide evidence for horizontal gene transfer in the mammalian gastrointestinal tract resulting in transgene-carrying wild type bacteria. These findings sound a strong note of caution on the employment of live genetically modified bacteria for the delivery of biologics.
format	article
author	Udo Wegmann Ana Lucia Carvalho Martin Stocks Simon R. Carding
author_facet	Udo Wegmann Ana Lucia Carvalho Martin Stocks Simon R. Carding
author_sort	Udo Wegmann
title	Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect
title_short	Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect
title_full	Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect
title_fullStr	Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect
title_full_unstemmed	Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect
title_sort	use of genetically modified bacteria for drug delivery in humans: revisiting the safety aspect
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/d47528c7b1b741b89f5e48981a26bc68
work_keys_str_mv	AT udowegmann useofgeneticallymodifiedbacteriafordrugdeliveryinhumansrevisitingthesafetyaspect AT analuciacarvalho useofgeneticallymodifiedbacteriafordrugdeliveryinhumansrevisitingthesafetyaspect AT martinstocks useofgeneticallymodifiedbacteriafordrugdeliveryinhumansrevisitingthesafetyaspect AT simonrcarding useofgeneticallymodifiedbacteriafordrugdeliveryinhumansrevisitingthesafetyaspect
_version_	1718394123540496384

Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect

Ejemplares similares